Pipeline
Addressing life-threatening, difficult-to-treat solid tumors
A2 Bio’s Pipeline
Our rich pipeline includes four pre-clinical programs with different clinically validated solid tumor targets. Tmod™ technology is modular, flexible and compatible with many types of immune cells, as well as manufacturing platforms. A2 Bio is focusing on the use of T cells for our initial pipeline.
Our pipeline
PROGRAM
ACTIVATOR
BLOCKER
INDICATIONS
COMMERCIAL RIGHTS
DISCOVERY
IND-ENABLING
PHASE 1
PHASE 2
AUTOLOGOUS
PROGRAM
A2B530
ACTIVATOR
CEA
BLOCKER
HLA-A*02
INDICATIONS
Colorectal, Lung and Pancreatic
COMMERCIAL RIGHTS
PROGRAM
A2B694
ACTIVATOR
MSLN
BLOCKER
HLA-A*02
INDICATIONS
Ovarian, Mesothelioma, Pancreatic, Colorectal, Lung
COMMERCIAL RIGHTS
ALLOGENEIC
PROGRAM
UNDISCLOSED
ACTIVATOR
UNDISCLOSED
BLOCKER
UNDISCLOSED
INDICATIONS
UNDISCLOSED
COMMERCIAL RIGHTS
PROGRAM
UNDISCLOSED
ACTIVATOR
UNDISCLOSED
BLOCKER
UNDISCLOSED
INDICATIONS
UNDISCLOSED
COMMERCIAL RIGHTS
PROGRAM
UNDISCLOSED
ACTIVATOR
UNDISCLOSED
BLOCKER
UNDISCLOSED
INDICATIONS
UNDISCLOSED
COMMERCIAL RIGHTS
Programs
Our two lead programs are autologous, followed by three allogeneic candidates. The Tmod™ platform is modular, enabling vast pipeline expansion opportunities. Additional therapies can be created by varying activator and blocker combinations.
Watch how Tmod™ T cells selectively kill tumor cells while sparing normal cells
A2 Bio’s candidate has been validated by robust pre-clinical in vitro and in vivo studies. Tmod™ CEA-targeted CAR T cells, A2B530, can seek CEA expressing tumors, then activate, proliferate and eliminate the tumors while protecting against activity on normal tissues.
Clinical trials
BASECAMP-1
BASECAMP-1 is a pre-screening protocol to identify potential eligible patients for our future trials. The objective of BASECAMP-1 is to use next-generation sequencing to collect information on solid tumor loss of human leukocyte antigen (HLA) and perform leukapheresis to collect and store eligible participants’ own T cells for future use to potentially make a CAR T cell therapy for their disease treatment. For more information and participating cell therapy sites of excellence, visit BASECAMP-1 (NCT04981119).